A clinical-stage biotech developing antibody drugs that target a mutated protein called calreticulin, which drives the blood disorders essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, was born at Paragon Therapeutics, a firm that launches drug companies from its own research — Damora was the sixth spun out. The company itself was once named Galecto and adopted the Damora name after acquiring the private firm behind DMR-001 in late 2025.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -1.48M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.